专利号:US-7288239-B2 优先权日:2002-11-21 标题:Method for producing alkaline earth sulphate nanoparticles 发明人:IBARRA FERNANDO; MEYER CHRISTIANE; HAUBOLD STEPHAN; HEIDELBERG THORSTEN 权利人:NANOSOLUTIONS GMBH 摘要:The invention relates to synthesis of nanoparticles, in particular to methods for producing nanoparticles with networks consisting of Z sulphate (Z=magnesium (Mg), calcium (Ca), strontium (Sr), barium (Ba) or the binary mixtures thereof). The inventive method consists in synthesising the nanoparticles by crystal growth from an ion Z source and a sulphate ion source in a liquid phase mixture. The invention produces Z sulphate nanoparticles having a small diameter and uniformly dispersible in water or other solvents in a simple way. Co-ordinating solvents like glycerine, glycol ethylene and other polyethylene glycols, polyalcohols or dimethylsulphoxide (DMSO) are used for the synthesis mixture.
1: Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, Agarwal P, Hull KL, Lyons KE, Johnson R, Stempien MJ. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. JAMA Neurol. 2017 Aug 1;74(8):941-949. doi: 10.1001/jamaneurol.2017.0943. doi: 10.1016/j.schres.2015.06.001. Epub 2015 Jun 21. Amantadine Effect on Perceptions of Irritability after Traumatic Brain Injury: Results of the Amantadine Irritability Multisite Study. J Neurotrauma. 2015 Aug 15;32(16):1230-8. doi: 10.1089/neu.2014.3803. Epub 2015 Mar 31. 4: Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, Struck L, Ruby AE, McClure NL, Went GT, Stempien MJ. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). Mov Disord. 2015 May;30(6):788-95. doi: 10.1002/mds.26159. Epub 2015 Feb 4. 5: Stryjer R, Budnik D, Ebert T, Green T, Polak L, Weizman S, Spivak B. Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label study. Clin Neuropharmacol. 2014 May-Jun;37(3):79-81. doi: 10.1097/WNF.0000000000000029. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology. 2014 Jan 28;82(4):300-7. doi: 10.1212/WNL.0000000000000050. Epub 2013 Dec 26. doi: 10.1097/01.HTR.0000438116.56228.de. doi: 10.1097/WNF.0b013e3182a9339d. doi: 10.1097/01.EJA.0000434967.03790.0e. doi: 10.1007/s00415-013-7108-7. Epub 2013 Sep 22. doi: 10.1097/WNF.0b013e31829bd066. doi: 10.3851/IMP2475. Epub 2012 Dec 21.
合成参考文献
参考文献:10.1007/s004010051054 摘要:Kornhuber J, Jellinger K, Wiltfang J, Leblhuber F, Riederer P. The N-methyl-D-aspartate receptor channel blocker amantadine does not cause histopathological alterations in human brain tissue. Acta Neuropathol. 1999 Jul;98(1):85–90. doi: 10.1007/s004010051054.